欧林生物：公司重组金葡菌疫苗Ⅲ期临床试验正常推进中

Core Viewpoint - The company is progressing normally with the Phase III clinical trial of the gold-staphylococcus vaccine, with no unblinding completed yet and no efficacy data results formed [2] Group 1: Clinical Trial Progress - The company expects to complete the initial and retesting of all serum samples by the end of Q1 this year [2] - Data cleaning is currently underway, with expectations to achieve a phase lock and conduct the first efficacy unblinding after obtaining serum test reports in the first half of this year [2] - The clinical trial progress and results may be influenced by various factors, and the final outcomes will be based on the company's public information [2]